ClinicalTrials.gg
CompletedNCT01862640Updated Dec 31, 2020Results posted

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

A Phase 3 interventional study of Brexpiprazole, OPC-34712 and Placebo Oral Tablet in Agitation Associated With, Alzheimer's Disease and Alzheimer's Type, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 85 sites in 7 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2020-12-31.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
433
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · Otsuka Holdings Co., Ltd..

Enrollment
3rd of 12
433 · median 265
Started
2013
with 1 other
Phase 3
13 of 17
none open now
Registered
8th of 17
by date

Among the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2013, is one of 13 in phase 3, and was the 8th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alzheimer Disease by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

To compare the efficacy of 2 fixed doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.

Read the detailed description

Behavioral symptoms, such as agitation, are core features in participants with Alzheimer's disease and related dementias and develop in the majority of dementia participants. The presence of agitation in participants with Alzheimer's disease places a significant burden not only on participants and their caregivers but also on the healthcare system.

This is a trial designed to assess the safety and efficacy of brexpiprazole in the treatment of participants with agitation associated with dementia of the Alzheimer's Type. The trial consists of a continuous 12-week double-blind treatment period with a 30-day follow-up. The trial population will include male and female participants between 55 and 90 years of age (inclusive) with a diagnosis of probable Alzheimer's disease, who are residing either in an institutionalized setting or in a non-institutionalized setting where the participant is not living alone.

03

Conditions studied

  • Agitation Associated With
  • Alzheimer's Disease
  • Alzheimer's Type
  • Mental Disorder
  • Nervous System Diseases

Keywords

  • OPC-34712
  • brexpiprazole
  • Dementia
  • Alzheimer's Disease
  • Cognitive Disorders
  • Agitation
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants 55 to 90 years of age, inclusive, at the time of .
  • Participants who are residing at their current location for at least 14 days before screening and are expected to remain at the same location for the duration of the trial.
  • Participants with a diagnosis of probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association.
  • Participants with a score of 5 to 22, inclusive, at screening and baseline visits.
  • Participants with onset of symptoms of agitation at least 2 weeks prior to the screening visit.
  • Participants with a score of ≥ 4 on the agitation/aggression item of the Neuropsychiatric Inventory-Nursing Home at the screening and baseline visits.
  • Participants who require pharmacotherapy for treatment of agitation per the investigator's judgment, after an evaluation for reversible factors (for example, pain, infection, polypharmacy) and a trial of nonpharmacological intervention.
  • Participants must have a previous magnetic resonance imaging or computed tomography of the brain, which was performed after the onset of symptoms of dementia, with findings consistent with the diagnosis of Alzheimer's disease.

Exclusion criteria

Exclusion Criteria:

  • Participants with dementia or other memory impairment not due to Alzheimer's disease
  • Participants with a history of stroke, well-documented , pulmonary or cerebral embolism.
  • Participants who currently have neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, gastrointestinal, or psychiatric disorders.
  • Participants who have been diagnosed with an Axis I disorder (, 4th edition, text revision criteria)
  • Participants with uncontrolled hypertension
  • Participants with uncontrolled insulin-dependent diabetes mellitus
  • Participants with epilepsy or a history of seizures
  • Participants considered in poor general health based on the investigator's judgment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
433 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo once daily

    Drug: Placebo Oral Tablet

  • Experimental
    Brexpiprazole 1 mg

    Titrate up from 0.25 milligrams (mg)/day brexpiprazole to 1 mg/day brexpiprazole

    Drug: Brexpiprazole, OPC-34712

  • Experimental
    Brexpiprazole 2 mg

    Titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole

    Drug: Brexpiprazole, OPC-34712

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment

    To compare the efficacy of 2 fixed doses (1 mg/day and 2 mg/day) of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type, by the assessment of CMAI after 12 weeks of treatment. The CMAI assesses the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consists of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score is 29, and the maximum possible CMAI total score is 203. A decrease in score indicates improvement in symptoms. To control the overall type I error at 0.05 level when making 2 comparisons of brexpiprazole doses versus placebo, statistical testing was carried out using a hierarchical testing procedure in the order of: 1) comparison of 2 mg/day brexpiprazole versus placebo, and 2) comparison of 1 mg/day brexpiprazole versus placebo.

    Time frame: Baseline, Week 12/Early Termination (ET)

Secondary outcomes

  1. Change From Baseline In The Clinical Global Impression-Severity Of Illness (CGI-S) Score, As Related To Symptoms Of Agitation After 12 Weeks Of Brexpiprazole Treatment

    To compare the efficacy of 2 fixed doses (1 mg/day and 2 mg/day) of brexpiprazole with placebo in participants with agitation associated with Alzheimer's dementia, by the assessment of CGI-S score after 12 weeks of treatment. The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicates improvement in symptoms.

    Time frame: Baseline, Week 12/ET

07

Results

Posted Jun 16, 2020
Limitations and caveats
None reported

Participant flow

Participants who met all the inclusion and none of the exclusion criteria were enrolled in this study. The study was conducted in 433 participants at 81 sites in 7 countries: Croatia, Germany, Serbia, Spain, Russia, Ukraine, and the United States.

Participant flow — Overall Study
MilestoneBrexpiprazole 0.5 mg/DayBrexpiprazole 1 mg/DayBrexpiprazole 2 mg/DayPlacebo
Started20137140136
Completed13121122121
Not completed7161815
Withdrew: Adverse event41068
Withdrew: Participant met withdrawal criteria1121
Withdrew: Participant withdrawn by investigator0111
Withdrew: Withdrawal by subject2485
Withdrew: Protocol deviation0010

Outcome measures

PrimaryChange From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment

To compare the efficacy of 2 fixed doses (1 mg/day and 2 mg/day) of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type, by the assessment of CMAI after 12 weeks of treatment. The CMAI assesses the frequency of agitated behaviors in elderly persons, such as hitting, cursing, and restlessness. It consists of 29 items all rated on a 1 to 7 scale with 1 being the "best" rating and 7 being the "worst" rating. The minimum possible CMAI total score is 29, and the maximum possible CMAI total score is 203. A decrease in score indicates improvement in symptoms. To control the overall type I error at 0.05 level when making 2 comparisons of brexpiprazole doses versus placebo, statistical testing was carried out using a hierarchical testing procedure in the order of: 1) comparison of 2 mg/day brexpiprazole versus placebo, and 2) comparison of 1 mg/day brexpiprazole versus placebo.

Time frame:
Baseline, Week 12/Early Termination (ET)
Reported as:
Least squares mean · units on a scale
Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment
units on a scaleBrexpiprazole 2 mg/DayBrexpiprazole 1 mg/DayPlacebo
Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment-21.6 ± 1.32-17.6 ± 1.33-17.8 ± 1.34
Statistical analysis
  • Brexpiprazole 2 mg/Day vs Placebo · Mixed-effect model repeated measure · p = =0.0404 · Least square (ls) mean difference: -3.77 · 95% CI -7.38 to -0.17
  • Brexpiprazole 1 mg/Day vs Placebo · Mixed-effect model repeated measure · p = =0.9015 · Ls mean difference: 0.23 · 95% CI -3.40 to 3.86
SecondaryChange From Baseline In The Clinical Global Impression-Severity Of Illness (CGI-S) Score, As Related To Symptoms Of Agitation After 12 Weeks Of Brexpiprazole Treatment

To compare the efficacy of 2 fixed doses (1 mg/day and 2 mg/day) of brexpiprazole with placebo in participants with agitation associated with Alzheimer's dementia, by the assessment of CGI-S score after 12 weeks of treatment. The CGI-S was used to rate the severity of agitation. Scores were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. A decrease in score indicates improvement in symptoms.

Time frame:
Baseline, Week 12/ET
Reported as:
Mean · units on a scale
Change From Baseline In The Clinical Global Impression-Severity Of Illness (CGI-S) Score, As Related To Symptoms Of Agitation After 12 Weeks Of Brexpiprazole Treatment
units on a scaleBrexpiprazole 2 mg/DayBrexpiprazole 1 mg/DayPlacebo
Change From Baseline In The Clinical Global Impression-Severity Of Illness (CGI-S) Score, As Related To Symptoms Of Agitation After 12 Weeks Of Brexpiprazole Treatment-1.29 ± 1.05-1.04 ± 1.12-1.08 ± 0.89
Statistical analysis
  • Brexpiprazole 2 mg/Day vs Placebo · Mixed-effect model repeated measure · p = =0.1566 · Ls mean difference: -0.16 · 95% CI -0.39 to 0.06
  • Brexpiprazole 1 mg/Day vs Placebo · Mixed-effect model repeated measure · p = =0.4440 · Ls mean difference: 0.09 · 95% CI -0.14 to 0.32

Adverse events

Collected over Adverse events (AEs) were collected throughout the study (Baseline to Week 12/ET).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole 0.5 mg/Day2/20 (10%)5/20 (25%)11/20 (55%)
Brexpiprazole 1 mg/Day2/137 (1.5%)11/137 (8%)27/137 (19.7%)
Brexpiprazole 2 mg/Day1/140 (0.7%)13/140 (9.3%)43/140 (30.7%)
Placebo0/135 (0%)7/135 (5.2%)29/135 (21.5%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventBrexpiprazole 0.5 mg/DayBrexpiprazole 1 mg/DayBrexpiprazole 2 mg/DayPlacebo
CellulitisInfections and infestations1/200/1370/1400/135
EncephalitisInfections and infestations1/200/1370/1400/135
FallInjury, poisoning and procedural complications1/200/1370/1400/135
Humerus FractureInjury, poisoning and procedural complications1/200/1370/1400/135
Haemorrhage IntracranialNervous system disorders1/200/1370/1400/135
AgitationPsychiatric disorders1/201/1371/1400/135
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders1/200/1371/1400/135
Urinary Tract InfectionInfections and infestations0/200/1374/1401/135
Duodenal Ulcer HaemorrhageGastrointestinal disorders0/200/1370/1401/135
PneumoniaInfections and infestations0/200/1370/1401/135
Most frequent other events
Showing 10 of 29
Most frequent other events
EventBrexpiprazole 0.5 mg/DayBrexpiprazole 1 mg/DayBrexpiprazole 2 mg/DayPlacebo
Blood Creatine Phosphokinase IncreasedInvestigations2/201/1371/1400/135
HeadacheNervous system disorders0/2012/13713/14011/135
DizzinessNervous system disorders0/201/1378/1404/135
InsomniaPsychiatric disorders0/207/1378/1406/135
AnaemiaBlood and lymphatic system disorders1/201/1372/1400/135
ConstipationGastrointestinal disorders1/201/1375/1401/135
Salivary HypersecretionGastrointestinal disorders1/200/1371/1400/135
AstheniaGeneral disorders1/202/1373/1403/135
Urinary Tract InfectionInfections and infestations1/202/1373/1401/135
FallInjury, poisoning and procedural complications1/200/1373/1402/135

Baseline characteristics

Age, Continuous
Age, Continuous(years)Brexpiprazole 0.5 mg/DayBrexpiprazole 1 mg/DayBrexpiprazole 2 mg/DayPlaceboTotal
Mean73.9 ± 9.173.8 ± 8.873.7 ± 8.174.1 ± 8.073.9 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole 0.5 mg/DayBrexpiprazole 1 mg/DayBrexpiprazole 2 mg/DayPlaceboTotal
Female12787970239
Male8596166194
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brexpiprazole 0.5 mg/DayBrexpiprazole 1 mg/DayBrexpiprazole 2 mg/DayPlaceboTotal
American Indian or Alaska Native00000
Asian01214
Native Hawaiian or Other Pacific Islander00000
Black or African American025512
White20134133130417
More than one race00000
Unknown or Not Reported00000
08

Study locations

85 sites
  • Tuscaloosa, Alabama 35404, United States
  • Phoenix, Arizona 85013, United States
  • Bellflower, California 90706, United States
  • Costa Mesa, California 92627, United States
  • Downey, California 90706, United States
  • Orange, California 92868, United States
  • Redlands, California 92373, United States
  • Yorba Linda, California 92886, United States
  • Norwalk, Connecticut 06851, United States
  • Coconut Creek, Florida 33024, United States
  • Hialeah, Florida 33012, United States
  • Hialeah, Florida 33013, United States
  • Hialeah, Florida 33018, United States
  • Lauderhill, Florida 33319, United States
  • Miami Springs, Florida 33166, United States
  • Miami, Florida 33122, United States
  • Miami, Florida 33126, United States
  • Miami, Florida 33136, United States
  • Miami, Florida 33137, United States
  • Miami, Florida 33145, United States
  • Miami, Florida 33161, United States
  • Miami, Florida 33174, United States
  • Sarasota, Florida 34239, United States
  • Decatur, Georgia 30033, United States
  • Suwanee, Georgia 30024, United States
  • Weymouth, Massachusetts 02190, United States
  • Saint Louis, Missouri 63128, United States
  • Saint Louis, Missouri 63141, United States
  • Las Vegas, Nevada 89148, United States
  • Manchester, New Jersey 08759, United States
  • Mount Arlington, New Jersey 07856, United States
  • Toms River, New Jersey 08755, United States
  • Hickory, North Carolina 28601, United States
  • Oklahoma City, Oklahoma 73118, United States
  • Franklin, Tennessee 37064, United States
  • Bedford, Texas 76022, United States
  • Waukesha, Wisconsin 53188, United States
  • Rijeka, 57000, Croatia
  • Zadar, 23000, Croatia
  • Zagreb, 10000, Croatia
  • Zagreb, 10090, Croatia
  • Mittweida, Saxony 09648, Germany
  • Achim, 28832, Germany
  • Berlin, 12209, Germany
  • Bielefeld, 33647, Germany
  • Bochum, 44791, Germany
  • Hamburg, 22083, Germany
  • Koln, 50935, Germany
  • Ostfildern, 73760, Germany
  • Westerstede, 26655, Germany
  • Ekaterinburg, 620030, Russian Federation
  • Samara, 443016, Russian Federation
  • Saratov, 410060, Russian Federation
  • St. Petersburg, 190000, Russian Federation
  • St. Petersburg, 190005, Russian Federation
  • St. Petersburg, 191119, Russian Federation
  • St. Petersburg, 192019, Russian Federation
  • St. Petersburg, 197341, Russian Federation
  • St. Petersburg, 198510, Russian Federation
  • Tonnel'nyy, 357034, Russian Federation
  • Belgrade, 11000, Serbia
  • Kovin, 26220, Serbia
  • Kragujevac, 34000, Serbia
  • Nis, 18000, Serbia
  • Novi Knezevac, 23330, Serbia
  • Novi Sad, 21000, Serbia
  • Vrsac, 26300, Serbia
  • Barcelona, 08028, Spain
  • Getafe, 28905, Spain
  • Girona, 17190, Spain
  • Madrid, 28034, Spain
  • Madrid, 28040, Spain
  • Madrid, 28049, Spain
  • Pamplona, 31014, Spain
  • Salamanca, 37003, Spain
  • Valencia, 46010, Spain
  • Valencia, 46026, Spain
  • Zamora, 49021, Spain
  • Kharkiv, 61068, Ukraine
  • Kherson, 73488, Ukraine
  • Kiev, 04080, Ukraine
  • Lviv, 79021, Ukraine
  • Odessa, 65006, Ukraine
  • Odessa, 67513, Ukraine
  • Poltava, 36013, Ukraine
09

References and documents

Publications

  • Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade RD, Cummings JL. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. Am J Geriatr Psychiatry. 2020 Apr;28(4):383-400. doi: 10.1016/j.jagp.2019.09.009. Epub 2019 Oct 1. PubMed 31708380 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Mar 2017, 44 months.

Results were first posted in Jun 2020, 3 years 3 months after primary completion. A results delay was requested in Jan 2018.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 44 months is close to that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2013
First posted
May 24, 2013
StartActual
Jul 11, 2013
Primary completionActual
Mar 15, 2017
CompletionActual
Mar 15, 2017
Results delay requested
Jan 22, 2018
Results first posted
Jun 16, 2020
Last update
Dec 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01862640
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
May 24, 2013
Start date
Jul 11, 2013
Primary completion
Mar 15, 2017
Completion
Mar 15, 2017
Results posted
Jun 16, 2020
Last update
Dec 31, 2020

Study contacts

Eva Kohegyi, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion